Merck & Co., Inc. (NYSE:MRK)
| CAPS Rating |
|
|---|---|
| Open | $37.94 |
| Previous Close | $38.15 |
| Daily Range | $37.78 - $38.01 |
| 52-Week Range | $29.47 - $39.43 |
| Market Cap | $116.79B |
| P/E Ratio | 34.40 |
| Dividend (Yield) | 1.68 (3.90%) |
| Volume | 10,352,913 |
| Average Daily Volume | 0 |
MRK
VS S&P 500 (SPY)
How do you think MRK will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MRK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MRK News and Commentary
- Glaxo Executive: Sales-Force Changes Have Helped Promoted-Product Sales – SmartMoney
- US STOCK FUTURES: HOT STOCKS TO WATCH – SmartMoney
- Pfizer Takes a Hit From Lipitor Loss But Outlook is Still Solid – Trefis
- US STOCK FUTURES: HOT STOCKS TO WATCH – SmartMoney
- FDA, Merck Warn Of Interaction With Hepatitis C Drug Victrelis, Some HIV Drugs – SmartMoney
- Here's 1 Reason Merck Looks Weak – The Motley Fool
- Modified Study, Same Bloody Results – The Motley Fool
- Buy, Sell, or Hold: Ariad Pharmaceuticals – The Motley Fool
- Higher Bleeding Haunts Merck Candidate - Analyst Blog – NASDAQ
- YCHARTS DIVIDEND DAILY: Some “Non-Royalty” Dividends Beat the Aristocrats – YCharts
- Why the Dow's Flat This Morning – The Motley Fool
- UPDATE: Merck Anti-Clotting Drug Meets Study Goal But Has Bleeding Risk – SmartMoney
- Merck: Vorapaxar Reduced Heart Attack Risk, But Raised Bleeding Risk – SmartMoney
- WSJ BLOG/Health: A.M. Vitals: Merck Will Apply for Suvorexant Approval This Year – SmartMoney
- Merck Investors Can Sleep Easier (Not Easy) – The Motley Fool
- Is This Situation Special Enough? – The Motley Fool
- Investments for Income Lovers – The Motley Fool
- The Highest-Yielding Dow Stocks – The Motley Fool
- The Best Dividend Yields From Dow Jones And NASDAQ – Trefis
- Merck Achieves Positive Results In Phase 3 Trials Of Insomnia Drug – SmartMoney
RSS Headlines
Fool UK
